XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Common Stock
Additional Paid-In-Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Total
Balance at beginning at Dec. 31, 2019 $ 3 $ 259,049 $ (6) $ (130,320) $ 128,726
Balance at beginning (in shares) at Dec. 31, 2019 28,567,837        
Exercise of stock options   112     112
Exercise of stock options (in shares) 103,385        
Vesting of restricted stock   30     30
Stock-based compensation expense   1,238     1,238
Disgorgement of stockholders' short-swing profits, net   52     52
Net unrealized gain (loss) on short-term marketable securities     51   51
Net loss       (11,886) (11,886)
Balance at ending at Mar. 31, 2020 $ 3 260,481 45 (142,206) 118,323
Balance at ending (in shares) at Mar. 31, 2020 28,671,222        
Balance at beginning at Dec. 31, 2019 $ 3 259,049 (6) (130,320) 128,726
Balance at beginning (in shares) at Dec. 31, 2019 28,567,837        
Net unrealized gain (loss) on short-term marketable securities         22
Net loss         (49,496)
Balance at ending at Sep. 30, 2020 $ 4 466,254 16 (179,816) 286,458
Balance at ending (in shares) at Sep. 30, 2020 34,720,675        
Balance at beginning at Dec. 31, 2019 $ 3 259,049 (6) (130,320) 128,726
Balance at beginning (in shares) at Dec. 31, 2019 28,567,837        
Net loss         (79,207)
Balance at ending at Dec. 31, 2020 $ 4 468,238 (3) (209,527) 258,712
Balance at ending (in shares) at Dec. 31, 2020 34,741,649        
Balance at beginning at Mar. 31, 2020 $ 3 260,481 45 (142,206) 118,323
Balance at beginning (in shares) at Mar. 31, 2020 28,671,222        
Exercise of stock options   9     9
Exercise of stock options (in shares) 3,202        
Vesting of restricted stock   13     13
Issuance of common stock pursuant to ESPP purchases   158     158
Issuance of common stock pursuant to ESPP purchases (in shares) 9,255        
Stock-based compensation expense   1,322     1,322
Net unrealized gain (loss) on short-term marketable securities     45   45
Net loss       (16,207) (16,207)
Balance at ending at Jun. 30, 2020 $ 3 261,983 90 (158,413) 103,663
Balance at ending (in shares) at Jun. 30, 2020 28,683,679        
Issuance of common stock upon closing of secondary public offering, net of issuance costs and underwriting fees $ 1 202,553     202,554
Issuance of common stock upon closing of secondary public offering, net of issuance costs and underwriting fees (shares) 6,012,390        
Exercise of stock options   163     163
Exercise of stock options (in shares) 24,606        
Vesting of restricted stock   9     9
Stock-based compensation expense   1,546     1,546
Net unrealized gain (loss) on short-term marketable securities     (74)   (74)
Net loss       (21,403) (21,403)
Balance at ending at Sep. 30, 2020 $ 4 466,254 16 (179,816) 286,458
Balance at ending (in shares) at Sep. 30, 2020 34,720,675        
Balance at beginning at Dec. 31, 2020 $ 4 468,238 (3) (209,527) 258,712
Balance at beginning (in shares) at Dec. 31, 2020 34,741,649        
Exercise of stock options   24     24
Exercise of stock options (in shares) 28,670        
Vesting of restricted stock   9     9
Stock-based compensation expense   2,364     2,364
Net unrealized gain (loss) on short-term marketable securities     1   1
Net loss       (15,090) (15,090)
Balance at ending at Mar. 31, 2021 $ 4 470,635 (2) (224,617) 246,020
Balance at ending (in shares) at Mar. 31, 2021 34,770,319        
Balance at beginning at Dec. 31, 2020 $ 4 468,238 (3) (209,527) $ 258,712
Balance at beginning (in shares) at Dec. 31, 2020 34,741,649        
Exercise of stock options (in shares)         123,523
Net unrealized gain (loss) on short-term marketable securities         $ (14)
Net loss         (68,353)
Balance at ending at Sep. 30, 2021 $ 4 476,521 (17) (277,880) 198,628
Balance at ending (in shares) at Sep. 30, 2021 34,875,302        
Balance at beginning at Mar. 31, 2021 $ 4 470,635 (2) (224,617) 246,020
Balance at beginning (in shares) at Mar. 31, 2021 34,770,319        
Exercise of stock options   393     393
Exercise of stock options (in shares) 60,333        
Vesting of restricted stock   9     9
Issuance of common stock pursuant to ESPP purchases   215     215
Issuance of common stock pursuant to ESPP purchases (in shares) 10,130        
Stock-based compensation expense   2,436     2,436
Net unrealized gain (loss) on short-term marketable securities     (7)   (7)
Net loss       (28,933) (28,933)
Balance at ending at Jun. 30, 2021 $ 4 473,688 (9) (253,550) 220,133
Balance at ending (in shares) at Jun. 30, 2021 34,840,782        
Exercise of stock options   219     219
Exercise of stock options (in shares) 34,520        
Vesting of restricted stock   2     2
Stock-based compensation expense   2,612     2,612
Net unrealized gain (loss) on short-term marketable securities     (8)   (8)
Net loss       (24,330) (24,330)
Balance at ending at Sep. 30, 2021 $ 4 $ 476,521 $ (17) $ (277,880) $ 198,628
Balance at ending (in shares) at Sep. 30, 2021 34,875,302